AzTrials
AzTrials

AnosmiaNCT07867184

Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)

An observational study of Anosmia and Chronic Obstructive Pulmonary Disease, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Background: Exposure to smoke increases the risk of many diseases. People can be exposed to dangerous levels of smoke during wildfires. Also, smoke from fires that burn manmade materials may contain toxic chemicals. Read more about this study

Who is it for?
Ages 18 to 65 years
How many people
350 participants
Where
1 siteUnited States
Study dates
29 Oct 2026to 31 Oct 2036
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Healthy firefighter cadets, recruits and active-duty firefighters aged 18 to 65 without history of recreational smoke exposure who are employed within the Maryland, Virginia, and the District of Columbia area.

Who may be able to join

  • To be eligible to participate in this study, an individual must meet all of the following criteria:
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Aged 18 to 65 at time of enrollment. Firefighters over the age of 65 may be enrolled per investigator discretion.
  • In good general health as evidenced by medical history.
  • Have or are willing to obtain a non-NIH primary physician who will manage all health conditions and be responsive for emergency medical treatment, if required.
  • Able to provide informed consent.
Show all 9Show fewer
  • Willing to allow biological samples and data to be stored for future research.
  • Have permission of active-duty command to participate in study.
  • Are an active-duty veteran or recruit firefighter eligible to participate in planned or unplanned firefighting scenarios.

Who cannot join

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Current use of tobacco, marijuana, vaping/e-cigarette or any illicit inhaled, ingested, or injected drugs within 1 year of enrollment.
  • Pregnancy or lactation.
  • Treatment with an investigational drug/intervention or immunosuppressive/immunomodulatory medications within 2 years of enrollment.
  • Current smoker, or tobacco use within 1 year of enrollment or greater than 5 pack-years cumulatively.
  • Conditions detailed as disqualifying under NFPA Form 1582 pertaining to 1) nose, oropharynx, trachea, and larynx and 2) lung and chest wall pathologies at time of enrollment.
Show all 20Show fewer
  • Known inborn error of immunity as cited by the most recent classification of the International Union of Immunological Societies.
  • Malignancy within 5 years.
  • Presence of condition(s) that, in the judgment of the investigator or the referring physician, may put the participant at undue risk or make them unsuitable for participation
  • in the study.
  • Participants will be selected in an equitable manner from the available pool of potentially eligible individuals, without regard to factors such as sex, race, ethnicity, socioeconomic status, etc, except for age, as described below. We note that, given their non-volunteer (ie salaried) status, active-duty firefighters and recruits are screened by NFPA Form 1582 for medical conditions precluding active firefighting duties, which is inclusive of above conditions with the exception of known inborn error of immunity.
  • Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the principal investigator. Study staff should be notified of co-enrollment on any other protocol.
  • -Adults Over the Age of 65
  • Federal firefighters have a maximum retirement age of 57 years; although there are local departments with individuals over this age. Firefighters over the age of 65 at enrollment who meet all other eligibility criteria will require special permission from investigators to participate in this study. Exceptions will be made on a case-by-case basis to ensure that age-matched cases do not skew disproportionately to an older population.
  • -Adults Who Lack, or Lose, Decision-Making Capacity to Consent to Research Participation
  • Given the known dangers associated with firefighting, it would be unethical to include individuals who lack decision-making capacity to consent.
  • -Exclusion During Pregnancy
  • Women who are/become pregnant will be excluded from the study while pregnant and/or lactating given condition specific physiology that may confound the objectives of the study. In the event of pregnancy in a study participant, the participant will temporarily pause all study related activities. Participants may resume study activities 4 weeks after the conclusion of the pregnancy or cessation of lactation.
  • -Children
  • Children will be excluded from this study given the age minimums to attend firefighting academies.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892

Other trials in United States

About this study

Background:

Exposure to smoke increases the risk of many diseases. People can be exposed to dangerous levels of smoke during wildfires. Also, smoke from fires that burn manmade materials may contain toxic chemicals. Researchers want to know more about how breathing smoke affects a person s airways (nose, sinuses, lungs) and immune system.

Read more

Objective:

To learn how exposure to smoke over time affects the health of people who work as firefighters.

Eligibility:

Healthy, nonsmoking people aged 18 to 65 years who work as firefighters. Some people older than 65 may also be included.

Design:

Participants will have study visits about every 6 months for up to 10 years. They will also have visits after a smoke exposure event. Some visits may be by telehealth. Each visit will include some or all of the following:

Imaging scans of the sinuses or chest.

Sample collection. These will include blood, nasal fluids, a skin swab, urine, and fluid coughed up from the lungs.

Lung function test. Participants will blow air into a machine that measures the volume moving in and out of their lungs.

Particles in exhaled air (PExA). Participants will breathe into a device that collects particles.

Heart function test.

Smell test. Participants will identify odors on scratch-and-sniff cards.

Wearable air monitors. Participants may be asked to wear a device that measures particles and chemicals in the air around them for 1 to 20 days.

International Public Safety Data Institute (IPSDI) reports. Participants will provide copies of these fire suppression event reports, if they are available.

Participants who have exams of the airways as part of their routine health care may have extra tissue samples collected for research.

Read the detailed description

Study Description:

This observational natural history study (FLARES) will define the acute and longterm airway, respiratory and immune consequences of anthropogenic smoke exposures that arise from urban and wildland urban interface (WUI) fires. Given their disproportionate exposure, firefighters will be used as a model. The protocol integrates (1) standardized clinical phenotyping, (2) detailed exposure assessment, and (3) multi-omic profiling to enable evidence-based management of smoke- and pollutant-related respiratory impairment.

FLARES will enroll firefighter recruits and active-duty firefighters. Firefighters will be followed longitudinally with twice annual visits to the NIH Clinical Center (NIH CC) and will undergo event-driven evaluations including paired pre- and postexposure assessments around planned fire exposures (eg, live fire simulations) and assessments following unplanned exposures. Systematic evaluation of the upper and lower airways will be coupled with an exposure-informed biorepository of biospecimens - blood, nasal lining fluid, particulates exhaled from deep airways and urine- for multi-omic and exposome analyses to elucidate molecular pathways of smoke- and chemical -related injury. Assessments will include sinus and chest imaging (baseline and 3-year CT with interval magnetic resonance imaging [MRI]), pulmonary function testing (PFT), and detailed exposure questionnaires. Pre/post exposure comparisons and longitudinal trajectories of firefighters will be used to identify early biomarkers, multi-omic trajectories, and clinical indices of perturbed respiratory immunity and sinopulmonary disease in relation to exposure characteristics (eg, frequency, duration, intensity, and fire type), including the growing burden of anthropogenic smoke exposures in the context of climate change.

Objectives:

Primary Objective: Assess changes in multi-omic signatures within airway epithelium/fluids, peripheral blood, and/or urine following anthropogenic smoke exposure.

Secondary Objective: Determine development or progression of upper and/or lower airway disease following anthropogenic smoke exposure at a 3-year interval.

Tertiary Objective: Assess multi-site exposome shifts following anthropogenic smoke exposure.

Exploratory Objectives:

  • Perform power calculations for untargeted metabolomic signatures using data from pilot of metabolomic pathway assessment of sigmaOH-fluorenes and sigmaOHphenanthrenes pre and post live fire simulator.
  • Assess multi-omic shifts following anthropogenic smoke exposure with standard fire department exposure collection data (eg, nature of biofuel, ambient conditions, personal protective equipment use and condition, decontamination practices).
  • Assess organ-specific blood biomarkers on basis of omics level analysis (eg, assess markers of end-neurologic damage in the event of metabolomics pathways suggestive of neurotoxic exposures such as lead or mercury).

Endpoints:

Primary Endpoints:

Fold differences in methylation, transcription, proteomic and/or metabolic pathways:

  • Initial pilot of metabolomic data will include pathway assessment of sigmaOHfluorenes and sigmaOH-phenanthrenes pre and post live fire simulator.
  • Comparing baseline to acute and subacute phases of anthropogenic smoke exposures (eg, firefighter specific monitoring of either planned or unplanned smoke exposure) relative to preceding baseline.
  • Comparing longitudinal changes within individual firefighters relative to time in service.

Primary endpoints may be assessed in context of acute exposures: 0-14 days after defined smoke exposure episode, subacute (15-90 days) post exposure, and chronic (repeated and/or > 90 days post exposure).

Secondary Endpoints: 3-year incidence of participant-reported symptoms corroborated by objective physiologic or inflammatory changes.

1 or more domains identified as meeting at least 1 subjective measure AND at least

1 corresponding objective measure (eg, Chronic Airway Assessment

Test [CAAT] >= 8 AND fractional exhaled nitric oxide [FeNO] > 50 ppb).

Tertiary Endpoint: Direct or estimated smoke chemical levels on wearable, under uniform monitors relative to neutral-location controls (eg, fire station or home) and post-exposure urine versus pre-exposure urine.

Exploratory Endpoints:

  • Power calculation for untargeted metabolomics experiments using pilot of metabolomic pathway assessment of sigmaOH-fluorenes and sigmaOHphenanthrenes pre and post live fire simulator.
  • Fold differences in methylation, transcription, proteomic and/or metabolic pathways in linear mixed-effects models adjusted for individual aspects of standard International Public Safety Data Institute (IPSDI) Exposure Tracker firefighter reporting systems.
  • Direct or estimated smoke chemical levels on wearable, under uniform monitors relative to neutral-location controls (eg, fire station or home) and post-exposure urine vs. pre-exposure in linear mixed-effects models adjusted for individual aspects of standard IPSDI Exposure Tracker firefighter reporting systems.
  • Comparing relative baselines of fire na(SqrRoot) ve recruits to recruits with prior exposure during standard firefighter academy training.
  • Serum levels of markers indicating end organ damage downstream of identified toxins with established organ-specific effect (eg, neurofilament light chain levels in the event of high lead and mercury levels).
Keywords
Firefighter, Respiratory, Smoke, Urban, Fire, Natural History
Medical subject headings
Anosmia, Pulmonary Disease, Chronic Obstructive, Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07867184
Study groupRoleWhat they receive
FirefightersHealthy firefighter cadets, recruits and active-duty firefighters aged 18 to 65 without history of recreational smoke exposure who are employed within the Maryland, Virginia, and the District of Columbia area.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fold differences in methylation, transcription, proteomic and/or metabolic pathways:1. After defined smoke exposure episode 2. Subacute post exposure 3. Chronic (repeated and/or > 90 days post exposure

    Assess changes in multi-omic signatures within airway epithelium/fluids, peripheral blood, and/or urine following anthropogenic smoke exposure

    Measured: 1. 0-14 days 2. 15-90 days 3. > 90 days

Secondary outcomes (1)
  1. Incidence of participant-reported symptoms corroborated by objective physiologic or inflammatory changes. 1 or more domains identified as meeting at least 1 subjective measure and at least 1 corresponding objective measure, eg, CAAT > 8 AND F...

    Determine development or progression of upper and/or lower airway disease following anthropogenic smoke exposure at a 3-year interval

    Measured: 3 year interval

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2026
  2. Study start29 Oct 2026 (estimated)
  3. Primary completion31 Oct 2031 (estimated)
  4. Study completion31 Oct 2036 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
350 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07867184
Sponsor's protocol ID
10002586
Other IDs
002586-I
Status last verified
6 Oct 2026
First submitted
8 Oct 2026
Last updated
26 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Raw de-identified data will be shared per NIH Data Sharing Policy and publication requirements.@@@@@@

Questions about this trial

What is this clinical trial studying?

An observational study of Anosmia and Chronic Obstructive Pulmonary Disease, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fold differences in methylation, transcription, proteomic and/or metabolic pathways:1. After defined smoke exposure episode 2. Subacute post exposure 3. Chronic (repeated and/or > 90 days post exposure (time frame: 1. 0-14 days 2. 15-90 days 3. > 90 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in